FibroGen (FGEN) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
FibroGen Reports Financial Results for the First Quarter of 2016
May 9, 2016 4:02 PM EDTContinued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data
Webcast Conference Call Scheduled for 4:30pm EST Today
SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) (FibroGen), a research-based biopharmaceutical company, today reported financial results for the quarter ended March 31, 2016.
We are pleased with the progress of our major development programs across the board, said Thomas B. Neff, chief executive officer of FibroGen. FibroGen and our collaboration partners continue to advance the roxadustat global Phase 3 program in... More
